The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.

The present disclosure relates to a method for generating variants of a protein based on a native protein regulated by allosteric pathway, the method comprising: i) providing 3D structures of the native protein; ii) identifying at least one pair of coupled allosteric sites within the amino acid sequence of the native protein named microswitch; iii) generating in silico mutations of said identified microswitch to generate a pool of variants; iv) computing at least one score reflecting the variation in allosteric coupling; and/or the variation in the relative stability v) predicting the activity of each variant compared to the native protein based on the computed score. The disclosure also concern a computer implemented program to carry out said method, and a variant of a protein or an active fragment thereof, a polynucleotide.

Natural killer cells are differentiated to an intraepithelial innate lymphoid cells (ielLC1)-like cell, with an increase in cytotoxic activity. Specifically, the disclosure provides a method for differentiating mammalian natural killer cells to adapt an ielLC1-like phenotype, the method comprising: differentiating peripheral natural killer (NK) cells in the presence of IL-15 and epithelial cells or plate coatings that mimic features of epithelial cells, to generate CD49a+ CD103+ cells having features and phenotype of ielLC1s, with enhanced cytotoxic activity and expression of Th1 type cytokines.

Provided herein are compositions and methods for altering sensitivity of target cells to killing by γδ T cells.

PDL1-pHLIP, a preparation method of the PDL1-pHLIP, and an application of the PDL1-pHLIP in treatment of autoimmune diseases are provided. A fusion peptide is prepared by binding a pH low insertion peptide and an extracellular domain of PDL1. The pH low insertion peptide may be inserted onto a cell membrane of a focus tissue in an acid environment; the PDL1 bound to the pH low insertion peptide is subjected to targeting localization at the focus by utilizing the above properties of the pH low insertion peptide; a PD-1/PD-L1 negative signal of the focus tissue is enhanced by utilizing the pH low insertion peptide; and immune response of effector T cells is suppressed at the source, thereby achieving an effect of preventing and treating the autoimmune diseases.

The present invention relates to a novel chimeric antigen receptor and to a pharmaceutical composition for preventing or treating containing the same.

The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro).sub.n-His-Pro-His-Ala-Arg-Ile-Lys].sub.m-Y. The peptides are for medical use, in particular as anti-tumoral agents.

The present invention relates to compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with coronavirus infections. The compositions comprise therapeutically effective amounts of a TLR2 agonist. Certain embodiments specify that the TLR2 agonist is a pegylated, palmitoylated-cysteine compound of Formula (I), (VI), (VII) or (VIII).